Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large B-Cell, Diffuse × tofacitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 7 Lymphoma, Follicular 7 Bronchiolitis Obliterans Syndrome 7 Pruritus 5 Arthritis, Rheumatoid 5 Plaque, Amyloid 1 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1 Cholangiocarcinoma 1 Arthritis, Psoriatic 1 Adenocarcinoma 1

Interventions

Rituximab 413 Cyclophosphamide 347 Vincristine 172 Prednisone 172 Doxorubicin 167 Etoposide 160 Peripheral Blood Stem Cell Transplantation 114 Filgrastim 108 Lenalidomide 97 fludarabine phosphate 96 Cytarabine 80 Radiotherapy 79 Gemcitabine 72 Melphalan 66 Mycophenolic Acid 64 Cyclosporine 60 Methotrexate 59 Busulfan 57 Ifosfamide 55 Carmustine 55 fludarabine 50 Tacrolimus 50 Whole-Body Irradiation 49 Carboplatin 49 polatuzumab vedotin 43 Oxaliplatin 43 Dexamethasone 43 Antilymphocyte Serum 42 ibrutinib 40 Bendamustine Hydrochloride 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05348213 2024-10-23

R-ICE+X

Ruijin Hospital

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡